Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy.

Article Details

Citation

Copy to clipboard

Ozbasar D, Toros U, Ozkaya O, Sezik M, Uzun H, Genc H, Kaya H

Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy.

J Obstet Gynaecol Res. 2010 Feb;36(1):133-7. doi: 10.1111/j.1447-0756.2009.01086.x.

PubMed ID

20178539 [ View in PubMed

]

Abstract

AIM: We prospectively aimed to investigate the relationship between raloxifene administration and serum malondialdehyde (MDA), nitric oxide (NO), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride levels in postmenopausal women undergoing hemodialysis treatment for chronic renal failure. METHODS: Twenty-four women scheduled for twice-weekly hemodialysis treatment were given 60 mg/day raloxifene for 3 months. Serum MDA, estimated NO, HDL, and LDL measurements were assessed initially and at month 3. We used the Mann-Whitney U and Wilcoxon signed-rank tests for comparisons. Five women discontinued the study. RESULTS: After controlling for baseline characteristics, mean serum MDA and estimated NO levels decreased (P = 0.0001 and P = 0.0001, respectively) from 2.01 +/- 0.40 micromol/L and 21.3 +/- 17.9 micromol/L at baseline to 1.27 +/- 0.23 micromol/L and 7.7 +/- 7.5 micromol/L at month 3, respectively. Mean serum LDL level declined (P = 0.004) from 120.0 +/- 24.3 mg/dL to 103.3 +/- 12.1 mg/dL, and mean HDL level increased (P = 0.024) from 52.2 +/- 7.8 mg/dL to 57.2 +/- 5.7 mg/dL with raloxifene administration. CONCLUSION: Oral raloxifene administration (60 mg/day) for 3 months lowered serum MDA and NO levels with favorable effects on serum lipid parameters in postmenopausal women, who were undergoing long-term hemodialysis treatment for chronic renal failure.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Raloxifene	Approved Investigational	Malondialdehyde	decreased	Raloxifene decreases the level of Malondialdehyde in the blood
Raloxifene	Approved Investigational	Estimated nitric oxide	decreased	Raloxifene decreases the level of Estimated nitric oxide in the blood
Raloxifene	Approved Investigational	HDL cholesterol	increased	Raloxifene increases the level of HDL cholesterol in the blood
Raloxifene	Approved Investigational	LDL cholesterol	decreased	Raloxifene decreases the level of LDL cholesterol in the blood